Prostate Cell News Volume 14.39 | Oct 13 2023

    By
    Bob
    -
    0
    29








    2023-10-13 | PCN 14.39


    Prostate Cell News by STEMCELL Technologies
    Vol. 14.39 – 13 October, 2023
    TOP STORY

    Prostate Cancer Progression Relies on the Mitotic Kinase Citron Kinase

    Researchers provided insights into regulation of aggressive prostate cancer (PCa) cell behavior by citron kinase (CIT) and identified CIT as a functionally diverse and druggable driver of PCa progression.
    [Cancer Research]

    Abstract
    Try proven workflows for your hPSC culture. Click to request your offer now.
    PUBLICATIONSRanked by the impact factor of the journal

    MYC Is a Regulator of Androgen Receptor Inhibition-Induced Metabolic Requirements in Prostate Cancer

    Scientists comprehensively characterized the effects of androgen receptor blockade on prostate cancer metabolism using transcriptomics, metabolomics, and bioenergetics approaches.
    [Cell Reports]

    Full ArticleGraphical Abstract

    Identification of the Mitochondrial Protein POLRMT as a Potential Therapeutic Target of Prostate Cancer

    RNA polymerase mitochondria (POLRMT) is essential for mitochondrial transcription machinery and other mitochondrial functions. Researchers explored its expression and potential functions in prostate cancer.
    [Cell Death & Disease]

    Full Article

    RNA-Binding Protein 14 Promotes Phase Separation to Sustain Prostate Specific Antigen Expression under Androgen Deprivation in Human Prostate Cancer

    RBM14 was found to be a novel factor involved in maintenance of prostate specific antigen expression via phase separation under androgen deprivation in prostate cancer.
    [Journal of Steroid Biochemistry and Molecular Biology]

    Abstract

    The Role of GCNT1 Mediated O-glycosylation in Aggressive Prostate Cancer

    Using in vitro and in vivo models, investigators showed that GCNT1 promoted the growth of prostate tumors and could modify the glycome of prostate cancer cells.
    [Scientific Reports]

    Full Article

    Conditional Knockout of PDK1 in Osteoclasts Suppressed Osteoclastogenesis and Ameliorated Prostate Cancer-Induced Osteolysis in Murine Model

    Deletion of 3-phosphoinositide-dependent protein kinase-1 (PDK1) in osteoclasts ameliorated osteolysis and reduced bone resorption markers in the murine model of prostate cancer-induced osteolysis.
    [European Journal of Medical Research]

    Full Article

    Photoactivation of Pheophorbide-A Utilizing 670 nm LEDs Elicits Cancer Suppressive Effects in Androgen-Independent Prostate Cancer Cellular Models

    Investigators showed that pheophorbide-a-photodynamic therapy substantially inhibited cell viability, anchorage-independent growth, and migration capacities and induced autophagy and apoptosis.
    [Journal of Pharmacy and Pharmacology]

    AbstractGraphical Abstract

    Berbamine Targets Cancer Stem Cells and Reverses Cabazitaxel Resistance via Inhibiting IGF2BP1 and P-STAT3 in Prostate Cancer

    The authors investigated the antitumor effect of berbamine, extracted from berberis amurensis, on prostate cancer stem cells.
    [The Prostate]

    Full Article

    The Synergistic Effects of Betanin and Radiotherapy in a Prostate Cancer Cell Line: An In Vitro Study

    Researchers evaluated the effects of betanin combined with radiation therapy as a potential radiosensitizing agent in the PC-3 cell line.
    [Molecular Biology Reports]

    Abstract
    A person presenting slides at a scientific conference
    REVIEWS

    The Role of NFATc1 in the Progression and Metastasis of Prostate Cancer: A Review on the Molecular Mechanisms and Signaling Pathways

    The authors highlight the role of NFATc1 in the progression and metastasis of prostate cancer and summarize the signaling pathways and molecular mechanisms, through which NFATc1 regulates the process of prostate cancer.
    [Cell Biology International]

    Abstract
    INDUSTRY AND POLICY NEWS

    UT Health San Antonio Becomes First Civilian Center in South Texas to Launch FDA-Approved Radiotherapy Treatment for Advanced Prostate Cancer

    The University of Texas Health Science Center at San Antonio (UT Health San Antonio) announced the successful launch of Pluvicto, a radiopharmaceutical used to treat patients with advanced metastatic prostate cancer.
    [UT Health San Antonio]

    Press Release
    FEATURED EVENT

    AACR-KCA Joint Conference on Precision Medicine in Cancer

    November 15 – 17, 2023
    Seoul, Korea

    > See All Events

    JOB OPPORTUNITIES

    Faculty Positions – Cancer Research

    University of Alabama at Birmingham – Birmingham, Alabama, United States

    Associate Professor – DNA Repair

    Stanford University – Stanford, California, United States

    Assistant/Associate Professor – Prostate Cancer

    Fred Hutchinson Cancer Center – Seattle, Washington, United States

    Postdoctoral Research Fellow – Prostate Cancer

    Cedars-Sinai – Los Angeles, California, United States

    Postdoctoral Associate – NMR-based Metabolomics and Metabolomic Imaging

    Massachusetts General Hospital – Boston, Massachusetts, United States

    > See All Jobs

    Submit an article, publication, job or event
    Brought to you by
    stemcell-logo-for newsletter-2
    Prostate Cell News Twitter